Aislinn Antrim, MA, Assistant Managing Editor

In the MAGNOLIA trial, the median duration of response was not reached at the median follow-up time of 8.3 months, with 85% of responders still in remission at 12 months.

Among patients treated with the combination of nivolumab and ipilimumab, 23% were alive at 3 years, compared to 15% of patients treated with chemotherapy.

Improvements in moderate-to-severe atopic dermatitis began quickly after the first dose of dupilumab, with improved itching in 1 week and skin clearance in 2 weeks.

With CAR T-cell therapies showing promise for follicular lymphoma and marginal zone lymphoma, clinicians must weigh toxicity and tolerability almost as strongly as efficacy because patients can live years with these diseases

Six-point plan outlines strategies to increase national vaccination rates, keep schools open, increase testing and masking access, and to relieve health systems that are overrun with COVID-19 patients.

The efficacy of pirtobrutinib does not depend on prior therapy, reason for prior BTK inhibitor discontinuation, or C481 mutation status, according to the presentation.

Empagliflozin demonstrated a 21% relative risk reduction for the composite primary endpoint of cardiovascular death or hospitalization for heart failure, compared with placebo.

Nearly 20% of patients with multiple myeloma have a form of the disease in which they make high quantities of a component of monoclonal proteins, which damages the kidneys.

In a study, 92.5% of patients treated with the 6-month regimen of Invega and 95% of patients treated with the 3-month regimen were relapse-free at 12 months.

Guarding against external air pollution while reducing the risk of infection when driving presents a challenge.

The nasal spray bypasses the gut and potential absorption issues associated with it, and offers consistent relief even when administered hours after the onset of a migraine attack.

The guidance noted it is preferable for immunocompromised patients to receive their third dose in a health care delivery setting rather than a pharmacy or public vaccination clinic.

Calls to poison control centers regarding the use of ivermectin for the prevention or treatment of COVID-19 have increased 5-fold since its baseline before the COVID-19 pandemic.

Atezolizumab was granted accelerated approval for the mTNBC indication in March 2019, making it the first immunotherapy agent to be approved in this setting.

The FDA has also converted the indication for pembrolizumab from an accelerated to a full, regular approval for patients with urothelial carcinoma.

Investigators found that 65% of patients with cancer and COVID-19 were hospitalized and 17% required admission or transfer to a higher level of care.

Although the average demand for tocilizumab increased by 279% during the study period, fill rates for orders by hospitals dropped from 99% to 45%.

In addition to early screening, counseling patients on preventive interventions can reduce the risk of developing prediabetes or type 2 diabetes.

This is the first time that the intravenous (IV) formulation of brivaracetam will be available for pediatric patients and is the only IV formulation approved for partial-onset seizures and this age group in nearly 7 years.

Silmitasertib has produced clinical benefit as a monotherapy and in combination with drugs such as gemcitabine and cisplatin.

The approval of Tibsovo marks the first and only targeted therapy approved for patients with previously treated IDH1-mutated cholangiocarcinoma.

At 30 days following the third dose in the series, the pneumococcal 15-valent conjugate vaccine was non-inferior to the 13-valent vaccine for all 13 shared serotypes.

Recent research has linked gut microbiota and cardiovascular disease with reported differences in gut microbial compositions among individuals with and without cardiovascular disease.

Tisagenlecleucel is a CD19-directed genetically modified autologous T cell immunotherapy already indicated for B-cell precursor acute lymphoblastic leukemia and diffuse large B-cell lymphoma.

Between 40% and 50% of patients respond long term without relapsing.

SARS-CoV-2 neutralizing titers against the wild-type strain one month after the booster dose were 3.3 times higher than the titers found one month after the second dose.

A final blinded analysis of data from the phase 3 COVE study found 93% efficacy of Moderna’s COVID-19 vaccine, which remained durable through 6 months after the second dose.

Researchers found that the levels of serum albumin and the number of metastatic sites that patients with lung cancer have were significantly associated with overall survival.

Although not all children are eligible for vaccination, recommendations for schools include masking, testing, and quarantine policies, as well as vaccinations for anyone eligible.

Rivaroxaban is the first and only therapy indicated for both coronary artery disease and peripheral artery disease.